Sponsors

Sponsor enrollment risk meeting agenda

A sponsor-facing meeting agenda for reviewing clinical trial enrollment risk, site blockers, source quality, recruitment movement, and next actions.

A useful enrollment risk meeting turns movement and blockers into decisions: what changed, where site execution or source quality is breaking down, who owns the next action, and what evidence will be reviewed next.

In this guide

Key points

  • Enrollment risk meetings should separate site execution, source quality, protocol friction, records delays, and scheduling capacity.
  • A useful agenda ends with decisions, owners, dates, and the next evidence point.
  • Sponsor updates should stay aggregate and operational rather than turning into patient-detail workspaces.

Start with movement since the last review

The first agenda item should be what changed: new inquiries, contacted patients, prescreened candidates, records requested, screening visits scheduled, screen failures, no-response closes, and enrolled participants where applicable.

Movement gives the sponsor a better operating picture than a static enrollment count. A site can be under target but improving, or on target while early pipeline risk is quietly building.

Review risk by blocker type

The agenda should separate risk categories such as low inquiry volume, low source quality, slow first follow-up, records delays, scheduling constraints, protocol criteria friction, language or access barriers, and site staffing limits.

Each blocker should have an owner and a proposed action. If the meeting only names the problem, the next meeting often repeats the same status with more urgency.

Include source quality and site execution

Sponsors should ask which sources are producing reachable, reviewable, and scheduled candidates. Volume alone can be misleading if many inquiries are duplicates, unreachable, out of geography, or missing required records.

Site execution should be reviewed separately from source performance. A strong source can look weak if the follow-up cadence is slow, and a weak source can consume coordinator time if close reasons are not tracked.

Close with decisions needed

The strongest enrollment risk meeting ends with decisions: shift source budget, revise patient-facing materials, add site support, adjust the cadence, prioritize records blockers, escalate a protocol question, or change reporting expectations.

TrialsNest supports sponsor reporting by making site movement, blockers, and next actions easier to review without replacing sponsor, CRO, investigator, or clinical decision-making responsibilities.

Illustrative example

A meeting that changes the next week

The sponsor sees two sites behind target. One has strong source quality but records delays; the other has high inquiry volume but weak scheduled movement. The agenda separates those risks so the actions are different.

Before: both sites are labeled behind plan and asked for more enrollment activity.

After: one action targets records workflow, while the other targets source quality and follow-up cadence.

What makes the meeting worth holding

If the agenda only repeats enrollment totals, it is a status readout. It becomes an operating meeting when the sponsor can decide whether to adjust source mix, support a site, clarify criteria, or change the reporting cadence.

Common mistakes

Opening with totals and never reaching blockers

Enrollment count matters, but the meeting needs the movement underneath it: new interest, contact rate, prescreen progress, records delays, scheduled visits, and close reasons.

Blending source quality with site execution

A weak source and a slow follow-up process can create the same enrollment symptom. The agenda should separate them before assigning action.

Before you start

  • Movement reviewed: Does the meeting compare new, contacted, prescreened, records-blocked, scheduled, closed, and enrolled movement?
  • Risk separated: Are source quality, site execution, protocol friction, records, and scheduling discussed as separate risks?
  • Decision recorded: Does each material risk end with an owner, action, date, and evidence point?
  • What changed since the last sponsor update?
  • Is the primary risk source quality, site execution, protocol friction, records, or scheduling?
  • Which decision needs an owner before the next meeting?
Sources and editorial notes

Published .

Sponsor reporting guidance for recruitment operations. It does not replace protocol, medical, regulatory, legal, CRO, or site oversight.

This information is educational. Your study team makes medical, eligibility, and enrollment decisions.

See TrialsNest in action

Bring this workflow into one place.

Manage inquiries, follow-ups, records, and visits. Keep sponsors updated on progress.

Aggregate study reporting

Sponsor portfolio

6 active studies482 inquiries18 research sites
Study APhase IIb

39 / 50 enrolled78%

Study BPhase III

74 / 120 enrolled62%

Study CPhase I

9 / 10 enrolled90%

Keep reading